Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Shareholder Meeting (August 2023)
7 slides from Radiopharm Theranostics's shareholder meeting presentation, Aug 18, 2023
Slide 1: Radiopharm Theranostics EGM Presentation
For personal use only RADIOPHARM THERANOSTICS EGM PRESENTATION 18 August 2023
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN
Slide 3: RAD accomplishments over the past 12 months
RAD accomplishments over the past 12 months For personal use only Pivalate Positive Phase 2a data in Brain Mets study October 2022 Trivehexin (Integrin) FDA IND approval received for Phase 1 in December 2022 pancreatic cancer Trivehexin (Integrin) Orphan Drug status granted for by FDA May 2023 Nanom
Slide 4: On the cusp of clinical data
On the cusp of clinical data Program T/D1 Development Timing Details For personal use only Q3 CY23: FDA IND approval a small Phase 2b trial with Patients: 30 Pivalate Dx potential to lead into a Phase 3 trial shortly after Finish*: Q2 CY24 Q3 CY23: Dosing of first patient in Phase 1 imaging trial in
Slide 5: Shareholder value creation late CY23 and into CY24
Shareholder value creation late CY23 and into CY24 Shareholder value is created when drugs are de-risked, we are focused on the “big changes in value” Moving into late stage human trials before commercialisation For personal use only Transferring the drug from animal models to human trials B
Slide 6: Significant Company transformation anticipated from preclinical to clinical stage
Significant Company transformation For personal use only anticipated from preclinical to clinical stage with 3 FDA IND trials in USA & 1 CTN/Ethics trial in Australia 6
Slide 7: Contact Us
For personal use only CONTACT US Riccardo Canevari Paul Hopper CEO & MANAGING DIRECTOR Executive Chairman Radiopharm Theranostics Limited Radiopharm Theranostics Limited T +1 862 309 0293 T +61 406 671 515 E rc@radiopharmtheranostic.com E paulhopper@lifescienceportfolio.com W www.radiopharmtheranost
Radiopharm Theranostics — Shareholder Meeting (August 2023) on 6ix